Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Uspehi Molekularnoj Onkologii
ISSN 2313-805X · eISSN 2413-3787 · ABC-press Publishing House · Russian Federation
Uspehi Molekularnoj Onkologii: impact factor 0.78 (journal website); fully open access; no APC; review about 8 weeks (community reports); 43 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Uspehi Molekularnoj Onkologii is published by ABC-press Publishing House. By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Cancer Cells and Metastasis and Cancer Immunotherapy and Biomarkers, together about 18.5% of its articles. Its main subfields are Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
The main objective of the journal Advances in Molecular Oncology is publication of current information on basic, clinical and experimental research in molecular oncology. The publication aim to provide insight into currently important areas of modern molecular oncology; present the most significant studies from Russian and foreign specialists in this field; create a forum for various researchers, including oncologists, molecular biologists, geneticists, biochemists, virologists, chemotherapists to share the results of their scientific research.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Editor-in-chief Mikhail A. Krasil’nikovPublisher website
Editorial board by country: none in mainland China; most named Russia 29, United States 2, Germany 1, Sweden 1, Serbia 1 (34 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology6.3%
- Cancer Cells and MetastasisMedicine6.3%
- Cancer Immunotherapy and BiomarkersMedicine5.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.6%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.3%
- Genetic factors in colorectal cancerMedicine5.1%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: RusSCI, ORCID
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 0.78Publisher website ·
- CiteScore 2026-06
- 0.6LetPub ·
- SJR 2026-06
- 0.13LetPub ·
- SJR (publisher)
- 12Publisher website ·
- SNIP 2026-06
- 0.11LetPub ·
- h-index
- 8OpenAlex ·
- i10-index
- 4OpenAlex ·
- 2-year mean citedness
- 0.49OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 424 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 27 | 27 | 0 |
| 2025 | 43 | 43 | 13 |
| 2024 | 41 | 41 | 41 |
| 2023 | 47 | 47 | 53 |
| 2022 | 41 | 41 | 46 |
| 2021 | 36 | 36 | 69 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 8 weeksLetPub ·
- Peer review
- Double anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| LetPub | No APC | No | — | |
| Publisher website | No APC | — | — |
Other charges and waivers (author guidelines)
- Page charges
- No page charges
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Keywords
- ≥ 3
- Reference style
- Numbered, in order of citation
- Cover letter
- Required
Article types accepted5
- clinical casesClinical cases – no more than 8 pages.Length not stated
- editorialsShort reports and editorials – 3 pages.Length not stated
- research articleResearch article should consist of the following sections: introduction; materials and methods; results; discussion; conclusion; acknowledgments (section is opt…Length not stated
- review articlesReview articles – up to 20 pages.Length not stated
- short reportsShort reports and editorials – 3 pages.Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, License & copyright, Peer review, Plagiarism, Preprints, Self-archiving
- Authorship 6.2.1 Authorship
According to the recommendations of the ICMJE, the right to be referred as the author have those persons who made significant contribution to the conception and design of the study or in the data analysis and its interpretation, actively participated in drafting the article or making fundamental changes, participated in the final approval of the version that is to be published and ready to take re…
Source ↗Publisher website ·- Conflicts of interest 6.2.2 Conflict of interest
At the end of the article you must specify conflicts of interest for all authors. Conflict of interest implies the existence of any relations and/or personal interest that potentially can affect results, interpretation of data, its objective perception, such as financial relations and cooperation with any organizations (e.g., receipt of fees, educational grants, participation in expert councils, m…
Source ↗Publisher website ·- License & copyright Copyright Notice
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License Model summary
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, addition…
Source ↗Publisher website ·- Peer review Peer Review Process
The journal is put on the Higher Attestation Commission list of periodicals (the list of leading peer-reviewed scientific journals recommended to publish the basic research results of doctor’s and candidate’s theses). Model summary
A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of "Advances in molecular oncology". This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer. Members of the editorial board and leading Russian and international experts in corresponding are…
Source ↗Publisher website ·- Plagiarism Borrowing and Plagiarism
Previously published articles will be discarded. Model summary
Publication of works containing plagiarism of text, ideas, data is prohibited. Authors should submit fully original works. Results of other authors’ work should be appropriately cited or quoted; quotations of a text previously published should be written as the direct speech with the obligatory indication of the original source. The editorial board of the journal checks the material using plagiari…
Source ↗Publisher website ·- Preprints Preprint and Postprint Policy
Prior to acceptance and publication in "Advances in molecular oncology" authors may make their submissions available as preprints on personal or public websites. As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in "Advances in molecular oncology" we suggest that the li…
Source ↗Publisher website ·- Self-archiving
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process Model summary
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- ABC-press Publishing House
- Country or region
- Russian Federation
- Language
- Russian
- ISSN
- 2313-805X
- Electronic ISSN
- 2413-3787
- Latest issue on the website
- Volume 13, Issue 2 (2026)
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Uspehi Molekularnoj Onkologii
What is the impact factor of Uspehi Molekularnoj Onkologii?
The journal's website gives an impact factor of 0.78; this is the journal's own figure, as LetPub lists none for it; CiteScore 0.6, h-index 8.
How long does peer review take at Uspehi Molekularnoj Onkologii?
Authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Uspehi Molekularnoj Onkologii?
According to the journal's author guidelines: Keywords: ≥ 3; Reference style: Numbered, in order of citation; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Uspehi Molekularnoj Onkologii based?
Of the 34 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Russia (29), United States (2) and Germany (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Uspehi Molekularnoj Onkologii?
According to LetPub and DOAJ records, Uspehi Molekularnoj Onkologii is indexed in Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is Uspehi Molekularnoj Onkologii open access, and what is the APC?
Uspehi Molekularnoj Onkologii is a fully open-access journal. It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .